Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.
Advertisement

Related Content

Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early

Topics

Advertisement
UsernamePublicRestriction

Register

PS071928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel